Gain Therapeutics Q2 net loss $0.19/sh; Phase 1b PD study fully enrolled, data by Q4 2025

Gain Therapeutics, Inc.

2025-Q2 EPS reported -$0.35 vs consensus -$0.17 ▼ miss (-103.8%)

Phase 1b of GT-02287 in Parkinson's reached target enrollment in Q2 2025 with 16 patients; up to 20 total.
Functional and biomarker analysis from 90-day dosing expected in Q4 2025; extension request submitted.
Net loss per share $0.19 vs $0.42 YoY; R&D spend down to $2.8M on grant income and credit.
Cash $6.7M as of June 30; July 2025 public offering raised ~$7.1M net, extending runway past Phase 1b.
IND submission to FDA for GT-02287 expected by year-end 2025 to enable US Phase 2 expansion.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.